Displaying drugs 10801 - 10825 of 11636 in total
Prinomastat
Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier.
Investigational
Matched Description: … As a lipophilic agent, prinomastat crosses the blood-brain barrier. ... Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. …
EHT899
EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Investigational
Matched Description: … EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune ... It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction …
Edivoxetine
Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant treatment. Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012.
Investigational
Matched Description: … Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under …
VY-HTT01
VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.
Investigational
Matched Description: … VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease ... VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses …
OSI-930
OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small...
Investigational
Morphine glucuronide
Investigational
Interleukin-7
Interleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer.
Investigational
Gam-COVID-Vac
Gam-COVID-Vac was created by Gamaleya Research Institute of Epidemiology and MIcrobiology in Russia. The vaccine candidate is a heterologous COVID-19 vaccine containing two components, recombinant adenovirus type 26 (rAd26) vector and recombinant adenovirus type 5 (rAd5) vector which both carry the SARS-CoV-2 spike glycoprotein. The vaccine is offered in both...
Investigational
Matched Description: … The vaccine candidate is a heterologous COVID-19 vaccine containing two components, recombinant adenovirus ... The vaccine is offered in both a frozen (Gam-COVID-Vac) and freeze-dried formulation (lyophilizate; Gam-COVID-Vac ... Preliminary results suggested that all participants developed antibodies to the SARS-CoV-2 glycoproteins with a …
XAV-19
XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on COVID-19 convalescent plasma. However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody that targets the spike protein of SARS-CoV-2[L16553,L16558]. The therapy offers three beneficial effects: the ability...
Investigational
Matched Description: … However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody ... As of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety ... Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University …
SLx-4090
SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes.
Investigational
Matched Description: … SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment …
Mitemcinal
Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.
Investigational
Matched Description: … Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin …
β-Hydroxythiofentanyl
β-Hydroxythiofentanyl is an analgesic of the opioid class. This drug is an analog of fentanyl, a potent opioid.
Illicit
Matched Description: … This drug is an analog of fentanyl, a potent opioid. …
Icrucumab
Icrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer).
Investigational
Matched Description: … Icrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal …
MS-1819
MS-1819 is under investigation in clinical trial NCT03481803 (A Phase IIa Study With Escalating Dose of MS1819-SD).
Investigational
Matched Description: … MS-1819 is under investigation in clinical trial NCT03481803 (A Phase IIa Study With Escalating Dose …
GSK-2981278
GSK-2981278 is under investigation in clinical trial NCT03004846 (A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis).
Investigational
Matched Description: … GSK-2981278 is under investigation in clinical trial NCT03004846 (A Study of GSK2981278 Ointment in Subjects …
Zagotenemab
Zagotenemab is under investigation in clinical trial NCT03518073 (A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease).
Investigational
Matched Description: … Zagotenemab is under investigation in clinical trial NCT03518073 (A Study of LY3303560 in Participants …
NM3086
NM3086 is a recombinant, humanized, aglycosylated, IgG1-kappa anti-properdin monoclonal antibody being developed by Novelmed Therapeutics Inc.
Experimental
Matched Description: … NM3086 is a recombinant, humanized, aglycosylated, IgG1-kappa anti-properdin monoclonal antibody being …
SAR422459
SAR422459 is a Lentiviral Vector Containing The Human Abca4 Gene that is currently being investigated to treat Stargardt disease.
Investigational
Matched Description: … SAR422459 is a Lentiviral Vector Containing The Human Abca4 Gene that is currently being investigated …
BRG01
BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.
Investigational
Matched Description: … BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of …
CTR-107
CTR-107 is a synthetic targeted growth factor. It is being investigated for the treatment of familial exudative vitreoretinopathy.
Investigational
Matched Description: … CTR-107 is a synthetic targeted growth factor. …
RC88
RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).
Investigational
Matched Description: … RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated …
TAK-071
TAK-071 is under investigation in clinical trial NCT04334317 (A Study of TAK-071 in People With Parkinson Disease).
Investigational
Matched Description: … TAK-071 is under investigation in clinical trial NCT04334317 (A Study of TAK-071 in People With Parkinson …
Beraprost
Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.
Investigational
Matched Description: … Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary …
Palifosfamide
Palifosfamide (ZIO-201) is a proprietary stabilized metabolite of ifosfamide. Ifosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.
Investigational
Matched Description: … Palifosfamide (ZIO-201) is a proprietary stabilized metabolite of ifosfamide. …
siG12D LODER
siG12D LODER is under investigation in clinical trial NCT01676259 (A Phase 2 Study of Sig12d LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer).
Investigational
Matched Description: … siG12D LODER is under investigation in clinical trial NCT01676259 (A Phase 2 Study of Sig12d LODER in …
Displaying drugs 10801 - 10825 of 11636 in total